Boundless Bio aims to treat the most aggressive cancers, which are frequently driven by ecDNA. The company’s initial therapeutic programs will pursue specific solid tumor types where ecDNA are highly prevalent. The company is also paving the way for a new understanding of extrachromosomal DNA, or ecDNA, one of the key drivers of the most aggressive cancers—specifically, those characterized by high copy number amplification of oncogenes. Building upon these insights, the company has  undertaken efforts to discover and develop proprietary treatments that exploit ecDNA’s unique vulnerabilities in precisely targeted patient populations.